ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Session » Health Services Research - Poster III

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

Abstract Number: 2227
Sustained Remission and Relapse Rate after Non-Conventional DMARD Withdrawal in Patients with Rheumatoid Arthritis
Abstract Number: 2228
Real-World Cost of Treating Inadequate Responders to Anti-Tumor Necrosis Factor Therapy
Abstract Number: 2229
Economic Burden of Rheumatoid Arthritis Is Higher for ACPA-Positive Patients
Abstract Number: 2230
Models Using Claims-Based Administrative Data Are Poor Predictors of Rheumatoid Arthritis Disease Activity in VA Rheumatoid Arthritis (VARA) Patients
Abstract Number: 2231
Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis
Abstract Number: 2232
Above-Label Dosing with Biologics in Treatment-NaïVe and Treatment-Experienced Patients with Moderate-to-Severe Psoriatic Arthritis
Abstract Number: 2233
Predictors of Adherence and Costs in First and Second Years after Biologic Initiation in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 2234
Economic Impact of Above-Label Dosing with Biologics in Patients with Moderate-to-Severe Psoriatic Arthritis
Abstract Number: 2235
Utilization of Ambulatory Physician Encounters, Emergency Room Visits and Hospitalizations By RA Patients: A 13 Year Population Health Study
Abstract Number: 2236
Effects of Repository Corticotropin Injection on Medication Use in Patients with Rheumatologic Conditions: A Claims Data Study
Abstract Number: 2237
Biologic DMARD Use Among U.S. Patients in an Online Rheumatoid Arthritis Community
Abstract Number: 2238
RA Medication Preferences Among U.S. Patients in an Online Rheumatoid Arthritis Community
Abstract Number: 2239
Patterns of Abatacept Utilization in Patients with Rheumatoid Arthritis. Have the Baseline Characteristics of These Patients Changed over Time?
Abstract Number: 2240
A Descriptive Analysis of Real-World Treatment Patterns in a Turkish Rheumatology Population That Continued Innovator Infliximab (Remicade) Therapy or Switched to Biosimilar Infliximab
Abstract Number: 2241
Health Economics of Uncontrolled Gout in the United States: A Systematic Literature Review
Abstract Number: 2242
Comparison of Assessment and Management of RA and Other Rheumatic Diseases By Rheumatologists in Private Practices or an Academic Medical Center
Abstract Number: 2243
The Paucity of the Evidence Base for American College of Rheumatology Practice Guidelines
Abstract Number: 2244
Utilization Patterns of Subcutaneously Administered Biologic Medications within a Sample of Rheumatoid Arthritis Patients
Abstract Number: 2245
Injectable Corticosteroid Use in Musculoskeletal Care Specialties
Abstract Number: 2246
Glucocorticoids in Early Rheumatoid Arthritis Management, Friend or Foe?
Abstract Number: 2247
REAL-Life Cost of UK Healthcare Resource for Patients with Rheumatoid Arthritis, Comparing High and Low/Remission Disease States
Abstract Number: 2248
The “Financial Toxicity” of Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 2249
Comparison of Discontinuation Rates Among Patients with RA Initiating Biologics
Abstract Number: 2250
A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes
Abstract Number: 2251
Secukinumab Vs Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis at 52 Weeks from the US Perspective
Abstract Number: 2252
Estimated Cost of SLE Hospitalizations
Abstract Number: 2253
Treatment Persistence with Subcutaneous TNF-Alpha Inhibitors in France
Abstract Number: 2254
Patient Adherence with Biologic Therapy in Rheumatoid Arthritis: A Real-World Review of Compliance

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.